Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Diffuse Astrocytoma, IDH-Mutant: early-phase trial registry

1 of 1 indexed Diffuse Astrocytoma, IDH-Mutant trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Diffuse Astrocytoma, IDH-Mutant: 1 US clinical trial tracked, 1 recruiting.

Diffuse Astrocytoma, IDH-Mutant is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Neonc Technologies, running 1 of these trials.

Enrollment posture brief

Registry condition diffuse-astrocytoma-idh-mutant

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Diffuse Astrocytoma, IDH (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Diffuse Astrocytoma, IDH-Mutant

Diffuse Astrocytoma, IDH-Mutant lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Diffuse Astrocytoma, IDH-Mutant on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Diffuse Astrocytoma, IDH-Mutant is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on Diffuse Astrocytoma, IDH-Mutant records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

NEO212 Oral Capsule Drug
1 trials
Regorafenib Drug
1 trials
Ipilimumab Drug
1 trials
Nivolumab Drug
1 trials
Pembrolizumab Drug
1 trials

US sites by state

Facility locations filed on Diffuse Astrocytoma, IDH-Mutant trials. A trial with sites in several states counts in each.

Washington 1 trials
Texas 1 trials
Tennessee 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Diffuse Astrocytoma, IDH-Mutant page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Diffuse Astrocytoma, IDH-Mutant trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Neonc Technologies sponsors the most Diffuse Astrocytoma, IDH-Mutant trials on record, review their full trial history before evaluating a specific study. See Neonc Technologies's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diffuse Astrocytoma, IDH-Mutant condition card totals 1 registered trials; most-linked intervention NEO212 Oral Capsule; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.